Patents Issued in April 1, 2004
  • PEPTIDOMIMETIC GLUTATHIONE ANALOGS
    Publication number: 20040063640
    Abstract: The invention relates to peptidomimetic compounds with formula 1
    Type: Application
    Filed: September 19, 2002
    Publication date: April 1, 2004
    Applicant: UNIVERSITEIT LEIDEN
    Inventors: Danny Burg, Gerard Johan Mulder
  • Use of growth hormone or a growth hormone secretagogue for promoting bone formation
    Publication number: 20040063641
    Abstract: The invention provides a method of enhancing the healing of bone fractures in an animal subjected to distraction osteogenesis, the method comprising administering, to the animal in need thereof, a growth hormone or a growth hormone secretagogue in an amount sufficient to provide bone formation simultaneous with the distraction procedure.
    Type: Application
    Filed: September 24, 2003
    Publication date: April 1, 2004
    Inventors: Michael Raschke, Henning Windhagen
  • Novel benzimidazolone peptidomimetics as thrombin receptor antagonists
    Publication number: 20040063642
    Abstract: The invention is directed to novel benzimidazolone peptidomimetic compounds which are useful as thrombin receptor antagonists for the treatment of diseases associated with thrombosis, restenosis, hypertension, heart failure, arrhythmia, inflammation, angina, stroke, atherosclerosis, ischemic conditions, Angiogenesis related disorders, cancer, and neurodegenerative disorders. Pharmaceutical compositions comprising the substituted benzimidazolone peptidomimetics of the present invention and methods of treating conditions mediated by the thrombin receptor are also disclosed.
    Type: Application
    Filed: March 17, 2003
    Publication date: April 1, 2004
    Inventors: Han-Cheng Zhang, Bruce E. Maryanoff, David F. McComsey, Kimberly B. White
  • Bombesin antagonists
    Publication number: 20040063643
    Abstract: Compounds of formula (I): 1
    Type: Application
    Filed: April 28, 2003
    Publication date: April 1, 2004
    Applicant: Pfizer Inc.
    Inventors: Michael Higginbottom, Suzanne Ross Kesten, Russell Andrew Lewthwaite, Martyn Clive Pritchard, David James Rawson, Robert Michael Schelkun, Po-Wai Yuen
  • Urea and urethane derivatives as integrin inhibitors
    Publication number: 20040063644
    Abstract: Novel urea and urethane derivatives of general formula (I) in which R1, R2, R3, R5, R5′, X, Y, B, m, n and o are as defined in Patent claim 1, and physiologically acceptable salts or solvates thereof are integrin inhibitors and can be employed for combating thromboses, cardiac infarction, coronary heart disease, arteriosclerosis, inflammation, tumours. Osteoporosis, infections and restenosis after angioplasty or in pathological processes maintained or propagated by antiogenesis.
    Type: Application
    Filed: June 18, 2003
    Publication date: April 1, 2004
    Inventors: Wolfgang Stahle, Alfred Joncyk, Oliver Schadt, Simon Goodman
  • Novel aromatic compounds possessing antifungal or antibacterial activity
    Publication number: 20040063645
    Abstract: The present invention provides novel compounds possessing antibacterial, antifungal, antiviral, anticancer, and/or antiparasitic activities. Pharmaceutical compositions containing these compounds, methods of making and methods for using these compounds are also provided.
    Type: Application
    Filed: September 18, 2003
    Publication date: April 1, 2004
    Inventors: Janos Botyanszki, Dong-Fang Shi, Christopher Don Roberts, Mikail Hakan Gezginci, Stephen Corey Valdez, Sherwin Sattarzadeh
  • Glucopyranosyloxypyrazole derivatives and use thereof in medicines
    Publication number: 20040063646
    Abstract: The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula: 1
    Type: Application
    Filed: November 6, 2003
    Publication date: April 1, 2004
    Inventors: Hideki Fujikura, Nobuhiko Fushimi, Toshihiro Nishimura, Takeshi Nakabayashi, Masayuki Isaji
  • Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
    Publication number: 20040063647
    Abstract: This invention relates to novel aldehyde containing compounds and their uses as adjuvants and immunoeffectors.
    Type: Application
    Filed: August 28, 2003
    Publication date: April 1, 2004
    Applicant: Corixa Corporation
    Inventor: David A. Johnson
  • Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
    Publication number: 20040063648
    Abstract: Disclosed are methods for treating, preventing, or inhibiting cancer in a subject comprising administering at least one polyphenolic compound and at least one inhibitor of reactive oxygen species to the subject. The polyphenolic compound may be derived or isolated from plants. In some embodiments, the polyphenolic compound is a flavonoid. In other embodiments, the polyphenolic compound is a non-flavonoid. Other methods and kits are also disclosed as well as pharmaceutical compositions.
    Type: Application
    Filed: October 1, 2002
    Publication date: April 1, 2004
    Inventors: Stephen J. Pandol, Anna Gukovskaya
  • Azithromycin combination for emesis control in mammals
    Publication number: 20040063649
    Abstract: The invention is directed to a method of treating cancer or a bacterial or protozoal infection in a mammalian subject in need of such treatment. The method comprises the adjunctive administration of pharmaceutically effective amounts of a macrolide antibiotic and a Substance P antagonist. The invention also encompasses a method of preventing or treating emesis associated with macrolide antibiotic administration. The invention further encompasses novel compositions comprising a macrolide antibiotic and a Substance P antagonist.
    Type: Application
    Filed: September 18, 2003
    Publication date: April 1, 2004
    Applicant: Pfizer Inc
    Inventors: Dennis M. Godek, Richard Todd Darrington, Elizabeth Fraering Illyes
  • Method for producing 3-methylthiopropanal
    Publication number: 20040063650
    Abstract: A 3-methylthiopropanal is produced by a method comprising the step of supplying an acrolein and a methyl mercaptan together or sequentially with an acidic compound and a basic compound into a reaction system to react the acrolein with the methyl mercaptan, wherein the basic compound is used in an amount of about 0.3 mol or less per mol of the acidic compound. In accordance with the present invention, a 3-methylthiopropanal with high quality is produced while suppressing the production of by-products having high boiling points.
    Type: Application
    Filed: September 22, 2003
    Publication date: April 1, 2004
    Applicant: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Tetsuya Shiozaki, Toru Haga
  • Remedies for hepatitis c
    Publication number: 20040063651
    Abstract: Excellent remedies for hepatitis C which contain as the active ingredients a 3′-deoxy-3′-fluorouridine derivatives and a 1-(3′-deoxy-fluoro-&bgr;-L-ribofuranosyl)uracil derivative and show little side effects.
    Type: Application
    Filed: July 31, 2003
    Publication date: April 1, 2004
    Inventors: Masahiko Morioka, Masaru Ubasawa, Masaaki Arai
  • Combination gene delivery vehicles
    Publication number: 20040063652
    Abstract: The combination of multiple, i.e., two or more, gene delivery vehicles (“GDVs”) with a pharmaceutically acceptable carrier or diluent to provide a pharmaceutically acceptable composition, and the administration of such a composition to an animal. The invention provides numerous advantages over previous methods of treating diseases or other pathogenic agents that included the use of a GDV, such as control of the level of expression of different genes carried by different GDVs, for example when it is preferred that the elicited response be predominantly against a gene product from one GDV, or if an immediate response is required from one GDV's gene product and a delayed or priming response is required from the other.
    Type: Application
    Filed: March 29, 2001
    Publication date: April 1, 2004
    Inventors: Douglas J. Jolly, Dominic Montisano
  • Polynucleotide vaccines expressing codon optimized hiv-1 pol and modified hiv-1 pol
    Publication number: 20040063653
    Abstract: Pharmaceutical compositions which comprise HIV Pol DNA vaccines are disclosed, along with the production and use of these DNA vaccines. The pol-based DNA vaccines of the invention are administered directly introduced into living vertebrate tissue, preferably humans, and preferably express inactivated versions of the HIV Pol protein devoid of protease, reverse transcriptase activity, RNase H activity and integrase activity, inducing a cellular immune response which specifically recognizes human immunodeficiency virus-1 (HIV-1). The DNA molecules which comprise the open reading frame of these DNA vaccines are synthetic DNA molecules encoding codon optimized HIV-1 Pol and codon optimized inactive derivatives of optimized HIV-1 Pol, including DNA molecules which encode inactive Pol proteins which comprise an amino terminal leader peptide.
    Type: Application
    Filed: September 30, 2002
    Publication date: April 1, 2004
    Inventors: John W. Shiver, Helen C. Perry, Danilo R. Casimiro, Tong-Ming Fu
  • Methods and compositions for therapeutic use of RNA interference
    Publication number: 20040063654
    Abstract: The present invention provides methods and compositions for attenuating expression of a target gene in vivo. In general, the method includes administering RNAi constructs (such as small-interfering RNAs (i.e., siRNAs) that are targeted to particular mRNA sequences, or nucleic acid material that can produce siRNAs in a cell), in an amount sufficient to attenuate expression of a target gene by an RNA interference mechanism, e.g., in a sequence-dependent, PKR-independent manner. In particular, the subject method can be used to alter the growth, survival or differentiation of cells for therapeutic and cosmetic purposes.
    Type: Application
    Filed: May 15, 2003
    Publication date: April 1, 2004
    Inventors: Mark E. Davis, Gregory S. Jensen, Suzie Hwang Pun
  • Antisense modulation of transforming growth factor-beta expression
    Publication number: 20040063655
    Abstract: Compositions and methods are provided for inhibiting the expression of TGF-&bgr;2. Antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding TGF-&bgr;2 are preferred. Methods of using these compounds for modulation of TGF-&bgr;2 expression and for treatment of diseases associated with expression of TGF-&bgr; are also provided.
    Type: Application
    Filed: August 1, 2003
    Publication date: April 1, 2004
    Inventors: Nicholas M. Dean, Susan Murray
  • Screening and therapy for lymphatic disorders involving the FLT4 receptor tyrosine kinase (VEGFR-3)
    Publication number: 20040063656
    Abstract: The present invention provides materials and methods for screening for and treating hereditary lymphedema in human subjects.
    Type: Application
    Filed: September 12, 2003
    Publication date: April 1, 2004
    Inventors: Robert E. Ferrell, Kari Alitalo, David N. Finegold, Marika Karkkainen
  • Antisense modulation of phosphoinositide-3-kinase, regulatory subunit 4, P150 expression
    Publication number: 20040063657
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of phosphoinositide-3-kinase, regulatory subunit 4, p150. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding phosphoinositide-3-kinase, regulatory subunit 4, p150. Methods of using these compounds for modulation of phosphoinositide-3-kinase, regulatory subunit 4, p150 expression and for treatment of diseases associated with expression of phosphoinositide-3-kinase, regulatory subunit 4, p150 are provided.
    Type: Application
    Filed: September 18, 2003
    Publication date: April 1, 2004
    Inventors: Susan M. Freier, Kenneth W. Dobie
  • Nucleoside derivatives for treating hepatitis C virus infection
    Publication number: 20040063658
    Abstract: Disclosed are compounds, compositions and methods for treating hepatitis C virus infections.
    Type: Application
    Filed: May 6, 2003
    Publication date: April 1, 2004
    Inventors: Christopher Don Roberts, Natalia B. Dyatkina, Jesse D. Keicher, Sebastian Johannes Reinhard Liehr, Eric Jason Hanson
  • Novel 2'-halomethylidene,2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives
    Publication number: 20040063659
    Abstract: This invention relates to certain novel 2′-halomethylidene, 2′-ethenylidene and 2′-ethynyl cytidine, uridine and guanosine derivatives, and compositions thereof, which are useful in the treatment of patients afflicted with neoplastic or viral disease states.
    Type: Application
    Filed: September 18, 2003
    Publication date: April 1, 2004
    Applicant: Merrell Pharmaceuticals Inc.
    Inventors: James R. McCarthy, Michael L. Edwards, Donald P. Matthews
  • Diasteriomers of S-adenosyl-l-methionine and uses thereof
    Publication number: 20040063660
    Abstract: Methods of use of administration of substantially optically pure diasteriomeric forms of S-adenosyl-l-methionine salts or defined non-racemic ratios of (S,S)-S-adenosyl-l-methionine to (R,S)-S-adenosyl-l-methionine and their salts in treating various conditions are described.
    Type: Application
    Filed: September 16, 2003
    Publication date: April 1, 2004
    Inventor: Rolland F. Hebert
  • Treatment of statin side effects
    Publication number: 20040063661
    Abstract: The present invention relates generally to treatment of muscle pain and/or fatigue and to methods for treatment of side effects of statin therapy. In particular, the invention relates to the use of certain substituted benzoquinones, e.g. Coenzymes Q, particularly Coenzyme Q10 (Q10), in therapy. The invention also relates to the use of Q10 in combinative therapy with other agents such as uridine, its biological precursors or salts, esters, tautomers or analogues thereof (“uridine related compounds”). The invention is also directed to compositions, uses and combination packs or kits related to the treatment methods.
    Type: Application
    Filed: October 8, 2003
    Publication date: April 1, 2004
    Inventor: Anthony William Linnane
  • Selenophene anti-tumor agents
    Publication number: 20040063662
    Abstract: Novel selenophene compounds useful as anti-tumor agents are described.
    Type: Application
    Filed: September 9, 2003
    Publication date: April 1, 2004
    Inventors: Ching-Jer Chang, Curtis L. Ashendel, Darrick Kim
  • Acylated cyclodextrin: guest molecule inclusion complexes
    Publication number: 20040063663
    Abstract: The present invention is directed to a method of making an inclusion complex comprising an acylated cyclodextrin host molecule and a guest molecule, wherein the method comprises the steps of: a) contacting the acylated cyclodextrin host molecule and the guest molecule to form an inclusion complex; and b) precipitating the inclusion complex in an aqueous medium. The present invention is further directed to an inclusion complex comprising an acylated cyclodextrin host molecule and a guest molecule, wherein the guest molecule comprises from about 2% (wt.) to about 15% (wt.) of the inclusion complex. Moreover, the present invention relates to a composition comprising a polymer and an inclusion complex, wherein the inclusion complex comprises an acylated cyclodextrin host molecule and a guest molecule and medical devices and solid pharmaceutical compositions comprised thereof.
    Type: Application
    Filed: September 30, 2003
    Publication date: April 1, 2004
    Inventors: Charles M. Buchanan, Matthew D. Wood, Jozsef Szejtli, Lajos Szente, Maria Vikmon
  • Simethicone containing tablet composition and method
    Publication number: 20040063664
    Abstract: A process and pharmaceutical composition containing simethicone and magnesium carbonate allows a higher production rate of simethicone containing tablets and a more consistent end product tablet. The magnesium carbonate prevents sticking of simethicone to tablet compressing apparatuses, and may also prevent sticking of other excipients to tablet compressing apparatuses.
    Type: Application
    Filed: September 30, 2002
    Publication date: April 1, 2004
    Inventors: Douglas W. Danielson, Steven S. Schuehle, Shirish A. Shah
  • Substituted benzopyranones as telomerase inhibitors
    Publication number: 20040063665
    Abstract: The present invention relates to benzopyranone derivative, to methods for treating telomerase-modulated diseases, in particular cancers, with said derivatives, to a process for their preparation, to their use as medicaments and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: September 16, 2003
    Publication date: April 1, 2004
    Inventors: Alberto Bargiotti, Luisella Bonomini, Maria Menichincheri, Jurgen Moll, Paolo Polucci, Chiara Soncini, Ermes Vanotti
  • Compositions for inhibiting arginase activity
    Publication number: 20040063666
    Abstract: Compositions and methods for inhibiting arginase activity, including arginase activity in a mammal, are provided. Methods of making the compositions of the invention are also provided as are methods of using the compositions therapeutically. The compositions described herein are useful for alleviating or inhibiting a variety of arinase- and NO synthase-related disorders, including heart diseae, gastrointestinal motility disorders, and penile erectile dysfunction in humans.
    Type: Application
    Filed: September 12, 2003
    Publication date: April 1, 2004
    Inventors: David Christianson, Ricky Baggio, Daniel Elbaum
  • Anti fibrotic agent containing sphingosine 1-phosphate receptor agonist or sphingosine 1-phospate as active ingredient
    Publication number: 20040063667
    Abstract: An anti fibrotic agent, comprising a sphingosine 1-phosphate (S1P) receptor agonist or sphingosine 1-phosphate (S1P) as an active ingredient. Since an S1P receptor agonist, particularly S1P, has activity of inhibiting fibrosis in various organs, it is useful in preventing and/or treating diseases caused by fibrosis in organs, such as pulmonary fibrosis, interstitial pneumonia, chronic hepatitis, hepatic cirrhosis, chronic renal failure, renal glomerulosclerosis, etc.
    Type: Application
    Filed: September 15, 2003
    Publication date: April 1, 2004
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Katsuya Kishikawa, Shigeru Matsumoto
  • Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same
    Publication number: 20040063668
    Abstract: The present invention relates to an acyclic nucleoside phosphonate derivative which is useful as an antiviral agent (particularly, against hepatitis B virus), pharmaceutically acceptable salts, stereoisomers, and a process for the preparation thereof.
    Type: Application
    Filed: June 18, 2003
    Publication date: April 1, 2004
    Inventors: Jong-Ryoo Choi, Jeong-Min Kim, Kee-Yoon Roh, Dong-Gyu Cho, Jae-Hong Lim, Jae-Taeg Hwang, Woo-Young Cho, Hyun-Sook Jang, Chang-Ho Lee, Tae-Saeng Choi, Chung-Mi Kim, Yong-Zu Kim, Tae-Kyun Kim, Seung-Joo Cho, Gyoung-Won Kim
  • Alpha-phenyl-beta-ketosulfone
    Publication number: 20040063669
    Abstract: The present invention relates to novel aryl-substituted S(O)m cycles of the formula (I) 1
    Type: Application
    Filed: June 13, 2003
    Publication date: April 1, 2004
    Inventors: Reiner Fischer, Oliver Kretschik, Thomas Schenke, Ralf-Ingo Schenkel, Jurgen Wiedemann, Christoph Erdelen, Peter Losel, Mark Wilhelm Drewes, Dieter Feucht, Wolfram Andersch
  • Use of bisphosphonates for pain treatment
    Publication number: 20040063670
    Abstract: A method for the treatment of pain, in particular antinociceptive or anti-allodynic treatment of pain, in a patient in need of such treatment, e.g. a patient with osteoporosis or osteopenia, a tumour patient or a patient suffering from an inflammatory disease, which comprises administering an effective amount of a bisphosphonate, e.g. zoledronic acid or salts or hydrates thereof, to the patient.
    Type: Application
    Filed: October 2, 2003
    Publication date: April 1, 2004
    Inventors: Alyson Fox, Jonathan Green, Terence O'Reilly, Laszlo Urban, Katharine Walker
  • Malonyl-coa decarboxylase inhibitors useful as metabolic modulators
    Publication number: 20040063671
    Abstract: The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD). In particular, the invention relates to compounds and compositions and the methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the inhibition of malonyl-coenzyme A decarboxylase.
    Type: Application
    Filed: July 21, 2003
    Publication date: April 1, 2004
    Inventors: Thomas Arrhenius, Mi Chen, Jie Fei Cheng, Yujin Huang, Alex Michael Nadzan, Sovouthy Tith, David Mark Wallace, Bin Liu, Masahiro Nishimoto
  • Method for the treatment of polycystic kidney disease
    Publication number: 20040063672
    Abstract: The present invention provides a method for treating, inhibiting the progression of, or eradicating polycystic kidney disease of in a patient in need thereof which comprises providing to said patient an effective amount of a TACE inhibitor compound alone or in combination with an effective amount of an EDF receptor kinase inhibitor.
    Type: Application
    Filed: October 2, 2003
    Publication date: April 1, 2004
    Inventors: Philip Frost, Jeremy I. Levin
  • Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
    Publication number: 20040063673
    Abstract: This invention provides compounds defined by Formula I
    Type: Application
    Filed: August 5, 2003
    Publication date: April 1, 2004
    Inventor: Adam Richard Johnson
  • Tetracycline compounds having target therapeutic activities
    Publication number: 20040063674
    Abstract: Methods and compounds for treating diseases with tetracycline compounds having a target therapeutic activity are described.
    Type: Application
    Filed: July 15, 2002
    Publication date: April 1, 2004
    Inventors: Stuart B. Levy, Michael Draper, Mark L. Nelson, Graham Jones
  • Synthesis of pancrastistatin
    Publication number: 20040063675
    Abstract: (+)-Narciclasine (2), available in quantity from certain Amaryllidaceae species or by total synthesis, is employed as relay for a ten step synthetic conversion (3.6% overall yield) to natural (+)-pancratistatin (1a). The key procedures involve the epoxidation of natural (+)-narciclasine (2) to an epoxide (6), reduction of the epoxide (6) to diol (8), formation of cyclic sulfate (12) and its ring opening with cesium benzoate followed by saponification of the benzoate to afford (+)-pancratistatin (1a).
    Type: Application
    Filed: June 17, 2003
    Publication date: April 1, 2004
    Inventors: George R. Pettit, Noeleen Melody
  • New use
    Publication number: 20040063676
    Abstract: The present invention relates to use of a composition for symptomatic relief, when needed, comprising, in admixture
    Type: Application
    Filed: September 19, 2003
    Publication date: April 1, 2004
    Applicant: AstraZeneca AB, a Swedish corporation
    Inventor: Tommy Ekstrom
  • Methods of treating disorders using lipophilic derivatives
    Publication number: 20040063677
    Abstract: The properties of biologically active compounds, for example drugs and agrochemicals, which contain in their molecular structure one or more functional groups selected from alcohol, ether, phenyl, amino, amido, thiol, carboxylic acid and carboxylic acid ester groups are modified by replacing one or more of these functional groups by a lipophilic group selected from those of the formula: RCOO—, RCONH—, RCOS—, RCH2O—, RCH2NH—, —COOCH2R, —CONHCH2R and —SCH2R, wherein R is a lipophilic moiety selected from cis-8-heptadecenyl, trans-8-heptadecenyl, cis-10-nonadecenyl and trans-10-nonadecenyl.
    Type: Application
    Filed: September 16, 2003
    Publication date: April 1, 2004
    Applicant: Norsk Hydro ASA
    Inventors: Finn Myhren, Bernt Borretzen, Are Dalen, Marit Liland Sandvold
  • Dexamethasone Gel
    Publication number: 20040063678
    Abstract: The invention relates to an ophthalmological preparation containing dexamethasone as the active ingredient and, optionally, also containing the usual additives and water, which is characterized by a content of at least one gel-forming pharmacologically acceptable substance in a quantity sufficient for adjusting the viscosity of the preparation as a gel.
    Type: Application
    Filed: September 18, 2003
    Publication date: April 1, 2004
    Applicant: Bausch & Lomb Incorporated
    Inventors: Gunther Bellmann, Gudrun Claus-Herz, Christoph Kessler
  • Compounds useful as reversible inhibitors of cysteine proteases
    Publication number: 20040063679
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (Ia) and (Ib) where R1, R2, R3, R4, R5, R6, R8, R9 and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.
    Type: Application
    Filed: September 27, 2002
    Publication date: April 1, 2004
    Applicant: Boehringer Ingelheim Pharmaceuticals Inc.
    Inventors: Younes Bekkali, Denice Mary Spero, Sanxing Sun, David S. Thomson, Yancey D. Ward, Erick R.R. Young, Eugene R. Hickey, Weimin Liu, Usha R. Patel
  • Method of treating stroke
    Publication number: 20040063680
    Abstract: The present invention provides a method of treating stroke in a patient comprising administering to said patient an effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 5, 2003
    Publication date: April 1, 2004
    Inventors: James Allen Clemens, David Lodge
  • Methods for using gold (III) complexes as anti-tumor and anti-HIV agents
    Publication number: 20040063681
    Abstract: Disclosed are pharmaceutical compositions comprising gold(III) complexes of porphyrins, Schiff-bases, bis(pyridyl)carboxamides and bis(pyridyl)sulfonamides. Also disclosed are methods for using the pharmaceutical compositions as anti-tumor and anti-HIV agents.
    Type: Application
    Filed: September 16, 2003
    Publication date: April 1, 2004
    Inventor: Chi-Ming Che
  • Preparation of aztreonam
    Publication number: 20040063682
    Abstract: The invention relates to a process for the synthesis of Aztreonam Specifically, the process entails hydrolyzing [3 S-[3&agr;(Z),4&bgr;]]-3-[[(2-amino-4-thiazolyl)[(1-t-butoxycarbonyl-1-methylethoxy)imino]acetyl]amino]-4-methyl-2-oxo-1-azetidinesulfonic acid (t-Bu Aztreonam) to form Aztreonam.
    Type: Application
    Filed: August 5, 2003
    Publication date: April 1, 2004
    Inventors: Viktor Gyollai, Erzsebet Meszaros Sos, Csaba Szabo, Claude Singer, Szabolcs Salyi
  • Novel carbapenem compounds
    Publication number: 20040063683
    Abstract: Carbapenem compounds having a substituted phenyl or a substituted thienyl directly attached to the 3-position of carbapenem nucleus as represented by the formula: 1
    Type: Application
    Filed: June 27, 2003
    Publication date: April 1, 2004
    Inventors: Makoto Sunagawa, Akira Sasaki
  • Treatment of oesophageal motility disorders and gastro-oesophageal reflux disease
    Publication number: 20040063684
    Abstract: Smooth muscle tone modulator compositions and methods of use thereof are provided for the treatment of oesophageal motility disorders and gastro-oesophageal reflux disease. The smooth muscle tone modulators are applied topically to treat the disorder. Topical treatment reduces the risk of undesirable side effects observed in connection with oral or sublingual administration of the modulators.
    Type: Application
    Filed: October 22, 2003
    Publication date: April 1, 2004
    Inventor: Michael A. Kamm
  • Combination Drugs
    Publication number: 20040063685
    Abstract: The present invention relates to a pharmaceutical agent containing an anti-sepsis drug (e.g., cycloalkene compound), and at least one kind of drug selected from the group consisting of an antibacterial agent, an antifungal agent, a non-steroidal antiinflammatory drug, a steroid and an anticoagulant in combination.
    Type: Application
    Filed: June 6, 2003
    Publication date: April 1, 2004
    Inventors: Juji Ilzawa, Masayuki Ii, Shohei Hashiguchi, Tomoyuki Kitazaki
  • Carboxamide compounds and their use as antagonists of a human 11cby receptor
    Publication number: 20040063686
    Abstract: Compounds of formula (I) in which: each A is independently hydrogen, C1-6alkyl optionally substituted by hydroxyl, C1-6alkoxy, C1-6alkenyl or C1-6acyl group or a halogen atom or hydroxyl, CN or CF3 group; R3 is hydrogen, methyl or ethyl; R4 is an optionally substituted aromatic carbocyclic or heterocyclic ring; Z is an O or S atom, or an NH or CH2 group, or a single bond, at the 3 or 4 position of R4 relative to the carbonyl group; R5 is an optionally substituted aromatic carbocyclic or heterocyclic ring, or an optionally substituted, saturated or unsaturated, carbocyclic or heterocyclic ring; and Q is (a) Where X, Y, R1 and R2 are as defined in claim 1; are antagonists of a human 11CBy receptor.
    Type: Application
    Filed: September 30, 2003
    Publication date: April 1, 2004
    Inventors: Christopher Norbert Johnson, Martin Jones, Catherine Anne O'Toole, Geoffrey Stemp, Kevin Michael Thewlis, David Witty
  • Heterocyclic dihydropyrimidine compounds
    Publication number: 20040063687
    Abstract: Novel heterocyclic dihydropyrimidine compounds useful as inhibitors of potassium channel function (especially inhibitors of the Kv1 subfamily of voltage gated K+ channels, especially inhibitors Kv1.5 which has been linked to the ultra-rapidly activating delayed rectifier K+ current IKur), methods of using such compounds in the prevention and treatment of arrhythmia and IKur-associated conditions, and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: September 12, 2003
    Publication date: April 1, 2004
    Inventors: Karnail S. Atwal, Wayne Vaccaro, John Lloyd, Heather Finlay, Lin Yan, Rao S. Bhandaru
  • Novel piperidine derivatives
    Publication number: 20040063688
    Abstract: A compound of the formula 1
    Type: Application
    Filed: July 8, 2003
    Publication date: April 1, 2004
    Applicant: Pfizer Inc.
    Inventors: Laura C. Blumberg, Matthew F. Brown, Matthew M. Hayward, Christopher S. Poss
  • Compositions containing alpha-2-adrenergic agonist components
    Publication number: 20040063689
    Abstract: Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.
    Type: Application
    Filed: October 22, 2003
    Publication date: April 1, 2004
    Applicant: Allergan, Inc.
    Inventors: Orest Olejnik, Edward D.S. Kerslake